The plasma hemostatic proteome: Thrombin generation in healthy individuals

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 7, 2005, Pages 1472-1481

  Brummel Ziedins, K ^a   Vossen, C Y ^b   Rosendaal, F R ^b   Umezaki, K ^a   Mann, K G ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Coagulation; Factor levels; Numerical simulators; Risk factors; Thrombin profiles

Indexed keywords

BLOOD CLOTTING INHIBITOR; PROTEOME; THROMBIN; THROMBOPLASTIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; COAGULATING AGENT; HEMOSTATIC AGENT;

ADULT; ANTICOAGULATION; ARTICLE; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; SIMULATION; AGE; ALGORITHM; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING TEST; CASE CONTROL STUDY; CHEMISTRY; HEMOSTASIS; METABOLISM; METHODOLOGY; MIDDLE AGED; PROTEOMICS; RISK; RISK FACTOR; STATISTICS; THEORETICAL MODEL; TIME; VEIN THROMBOSIS;

ADULT; AGE FACTORS; ALGORITHMS; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; COAGULANTS; FEMALE; HEMOSTASIS; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROTEOME; PROTEOMICS; RISK; RISK FACTORS; STATISTICS; THROMBIN; THROMBOPLASTIN; TIME FACTORS; VENOUS THROMBOSIS;

EID: 25144463563     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01249.x     Document Type: Article

References (62)

1. Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Buller HR. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
2. Quick AJ. The prothrombin time in haemophilia and in obstructive jaudice. J Biol Chem 1935; 109: 73-4.
3. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests: a presumptive test of hemophilia and a single one-stage anti-hemophilic factor assay procedure. J Lab Clin Med 1953; 41: 7637-47.
4. van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. Semin Hematol 1997; 34: 188-204.
5. Harper PL, Luddington RJ, Daly M, Bruce D, Williamson D, Edgar PF, Perry DJ, Carrell RW. The incidence of dysfunctional anti-thrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol 1991; 77: 360-4.
6. Lu D, Bovill EG, Long GL. Molecular mechanism for familial protein C deficiency and thrombosis in protein C Vermont (Glu20 → Ala and Val34 → Met). J Biol Chem 1994; 269: 29032-8.
7. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001; 85: 584-95.
8. Patel RK, Ford E, Thumpston J, Arya R. Risk factors for venous thrombosis in the black population. Thromb Haemost 2003; 90: 835-8.
9. Bhattacharyya M, Kannan M, Chaudhry VP, Saxena R. Venous thrombosis: prevalence of prothrombotic defects in north Indian population. Indian J Pathol Microbiol 2003; 46: 621-4.
10. Doggen CJ, Cats VM, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-41.
11. Nicolaes GA, Dahlback B. Activated protein C resistance (FV (Leiden)) and thrombosis: factor V mutations causing hypercoagulable states. Hematol Oncol Clin North Am 2003; 17: 37-61.
12. Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJ, Reitsma PH. The 20210 G → A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haematol 1999; 104: 50-4.
13. Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie Y. Combined carrier status of prothrombin 20210A and factor XIIIA L34 alleles as a strong risk factor for myocardial infarction evidence of a gene-gene interaction. Blood 2000; 101: 3037-41.
14. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
15. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 3678-82.
16. Lavigne G, Mercier E, Quere I, Dauzat M, Gris JC. Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. J Thromb Haemost 2003; 1: 2134-9.
17. Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, Manigrasso MR, Basili S, Davi G. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab 2003; 88: 5321-6.
18. Rauramaa R, Vaisanen SB. Physical activity in the prevention and treatment of a thrombogenic profile in the obese: current evidence and research issues. Med Sci Sports Exerc 1999; 31: S631-S634.
19. Rosendaal FR, van Hylckama Vlieg HA, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003; 1: 1371-80.
20. Rosing J, Tans G. Effects of oral contraceptives on hemostasis and thrombosis. Am J Obstet Gynecol 1999; 180: S375-S382.
21. Haapanen-Niemi N, Vuori I, Pasanen M. Public health burden of coronary heart disease risk factors among middle-aged and elderly men. Prev Med 1999; 28: 343-8.
22. Catena C, Novello M, Dotto L, De Marchi S, Sechi LA. Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage. J Hypertens 2003; 21: 281-8.
23. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-45.
24. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-52.
25. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
26. Brummel-Ziedins KE, Pouliot RL, Mann KG. Thrombin generation: phenotypic quantitation. J Thromb Haemost 2004; 2: 281-8.
27. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
28. Hartert HS. The physical and biological constants of thrombelastography. Biorheology 1962; 1: 31-9.
29. Carr ME Jr, Martin EJ, Carr SL. Delayed, reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation. Blood Coagul Fibrinolysis 2002; 13: 193-7.
30. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: 551-8.
31. Mann KG, Butenas S, Brummel KE. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003; 23: 17-25.
32. Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
33. Nakagaki T, Foster DC, Berkner KL, Kisiel W. Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 1991; 30: 10819-24.
34. Jesty J, Silverberg SA. Kinetics of the tissue factor-dependent activation of coagulation factors IX and X in a bovine plasma system. J Biol Chem 1979; 254: 12337-45.
35. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
36. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 23357-66.
37. Butenas S, DiLorenzo ME, Mann KG. Ultrasensitive fluorogenic substrates for serine proteases. Thromb Haemost 1997; 78: 1193-201.
38. Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
39. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
40. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-30.
41. Hemker HC, Giesen PAI, Dieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
42. Brummel KE, Paradis SG, Branda RF, Mann KG. Oral anticoagulation thresholds. Circulation 2001; 104: 2311-7.
43. Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, Beguin S. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-82.
44. Butenas S, Cawthern KM, van't Veer C, DiLorenzo ME, Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001; 97: 2314-22.
45. You L. Toward computational systems biology. Cell Biochem Biophys 2004; 40: 167-84.
46. Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 1994; 269: 23367-73.
47. Kuharsky AL, Fogelson AL. Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. Biophys J 2001; 80: 1050-74.
48. Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322-33.
49. Adams TE, Everse SJ, Mann KG. Predicting the pharmacology of thrombin inhibitors. J Thromb Haemost 2003; 1: 1024-7.
50. Orfeo T, Brufatto N, Nesheim ME, Xu H, Butenas S, Mann KG. The factor V activation paradox. J Biol Chem 2004; 279: 19580-91.
51. Brummel-Ziedins KE, Pouliot R, Butenas S, Mann KG. Factor VIIa replacement therapy in factor VII deficiency. J Thromb Haemost 2004; 2: 1735-44.
52. Butenas S, Orfeo T, Gissel MT, Brummel KE, Mann KG. The significance of circulating factor IXa in blood. J Biol Chem 2004; 279: 22875-82.
53. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631-5.
54. Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM. Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 2000; 20: 1382-6.
55. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-3.
56. Dahm A, van Hylckama V, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-92.
57. de Visser MC, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 2001; 85: 1011-7.
58. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
59. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-22.
60. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
61. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9.
62. Butenas S, van't Veer C, Mann KG. 'Normal' thrombin generation. Blood 1999; 94: 2169-78.